Symbols / DMAC $7.95 +2.05%
DMAC Chart
About
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 414.02M |
| Enterprise Value | 358.96M | Income | -31.93M | Sales | — |
| Book/sh | 0.99 | Cash/sh | 1.06 | Dividend Yield | — |
| Payout | 0.00% | Employees | 27 | IPO | — |
| P/E | — | Forward P/E | -10.52 | PEG | — |
| P/S | — | P/B | 8.02 | P/C | — |
| EV/EBITDA | -10.70 | EV/Sales | — | Quick Ratio | 10.55 |
| Current Ratio | 10.67 | Debt/Eq | 0.52 | LT Debt/Eq | — |
| EPS (ttm) | -0.71 | EPS next Y | -0.76 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-17 | ROA | -38.33% |
| ROE | -64.12% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 52.08M |
| Shs Float | 27.34M | Short Float | 12.15% | Short Ratio | 19.26 |
| Short Interest | — | 52W High | 10.42 | 52W Low | 3.19 |
| Beta | 1.10 | Avg Volume | 256.35K | Volume | 189.13K |
| Target Price | $15.50 | Recom | Strong_buy | Prev Close | $7.79 |
| Price | $7.95 | Change | 2.05% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.50
Mean price target
2. Current target
$7.95
Latest analyst target
3. DCF / Fair value
$-5.92
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.95
Low
$11.00
High
$25.00
Mean
$15.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-14 | init | Cantor Fitzgerald | — → Overweight | $25 |
| 2025-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-07-18 | main | Craig-Hallum | Buy → Buy | $11 |
| 2025-07-18 | main | Lake Street | Buy → Buy | $14 |
| 2025-07-18 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-19 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-10-10 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-10-07 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2024-08-16 | reit | Oppenheimer | Outperform → Outperform | $6 |
| 2024-03-21 | main | Craig-Hallum | Buy → Buy | $8 |
| 2024-03-21 | reit | Oppenheimer | Outperform → Outperform | $6 |
| 2023-06-22 | up | Oppenheimer | Perform → Outperform | $7 |
| 2022-07-07 | main | Lake Street | — → Buy | $8 |
| 2022-07-07 | main | Craig-Hallum | — → Buy | $12 |
| 2022-07-07 | down | Oppenheimer | Outperform → Perform | — |
| 2021-06-30 | main | Roth Capital | — → Buy | $32 |
| 2021-04-08 | init | Oppenheimer | — → Outperform | $27 |
| 2021-02-17 | init | Roth Capital | — → Buy | $38 |
- DiaMedica Therapeutics, Inc. $DMAC Shares Purchased by Paragon Associates & Paragon Associates II Joint Venture - MarketBeat Sat, 07 Mar 2026 11
- Canada clears trial of new drug for dangerous preeclampsia - Stock Titan hu, 05 Mar 2026 12
- Aug Weekly: Can DMAC stock outperform in 2026 bull market - Naître et grandir Sat, 07 Mar 2026 02
- What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now? - Yahoo Finance hu, 28 Aug 2025 07
- DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences - Business Wire ue, 24 Feb 2026 08
- $DMAC stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Fri, 16 Jan 2026 08
- Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade - Nasdaq Mon, 08 Sep 2025 07
- Insiders continue to buy DiaMedica Therapeutics Inc. (NASDAQ:DMAC) and now own 47% shares - simplywall.st Sat, 24 Jan 2026 08
- DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Monday - MarketBeat Mon, 09 Mar 2026 06
- DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia (NASDAQ:DMAC) - Seeking Alpha Wed, 13 Aug 2025 07
- Dow Update: Whats the fair value of DMAC stock - Weekly Gains Report & Accurate Trade Setup Notifications - baoquankhu1.vn Sat, 07 Mar 2026 06
- DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy? - Nasdaq Wed, 17 Sep 2025 07
- With 48% ownership, insiders at DiaMedica Therapeutics Inc. (NASDAQ:DMAC) are pretty optimistic and have been buying recently - Yahoo Finance ue, 04 Nov 2025 08
- DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire Fri, 16 Jan 2026 08
- DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price Down 2.1% - Time to Sell? - MarketBeat Mon, 02 Mar 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10095 | 85000 | — | Stock Award(Grant) at price 8.42 per share. | PARSONS JAMES T CPA | Director | — | 2026-01-02 00:00:00 | D |
| 1 | 6175 | 51994 | — | Stock Award(Grant) at price 8.42 per share. | GIUFFRE RANDALL MICHAEL M.D. | Director | — | 2026-01-02 00:00:00 | D |
| 2 | 3355 | 28249 | — | Stock Award(Grant) at price 8.42 per share. | SEMBA CHARLES PAULING | Director | — | 2026-01-02 00:00:00 | D |
| 3 | 1061277 | 7631469 | — | Purchase at price 6.52 - 8.57 per share. | STAHLBERG JAN | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-25 00:00:00 | I |
| 4 | 12000 | 26400 | — | Conversion of Exercise of derivative security at price 2.20 per share. | PARSONS JAMES T CPA | Director | — | 2025-11-21 00:00:00 | D |
| 5 | 1000000 | 5958107 | — | Purchase at price 5.86 - 6.00 per share. | STAHLBERG JAN | Beneficial Owner of more than 10% of a Class of Security | — | 2025-08-27 00:00:00 | I |
| 6 | 400000 | 2060000 | — | Purchase at price 5.15 per share. | JACINTO RICHARD II | Beneficial Owner of more than 10% of a Class of Security | — | 2025-07-23 00:00:00 | I |
| 7 | 2857142 | 14714281 | — | Purchase at price 5.15 per share. | VON KOCH NILS THOMAS | Beneficial Owner of more than 10% of a Class of Security | — | 2025-07-23 00:00:00 | I |
| 8 | 1542857 | 7945714 | — | Purchase at price 5.15 per share. | STAHLBERG JAN | Beneficial Owner of more than 10% of a Class of Security | — | 2025-07-23 00:00:00 | I |
| 9 | 24000 | 50640 | — | Conversion of Exercise of derivative security at price 2.11 per share. | PILNIK RICHARD D | Director | — | 2025-04-07 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -26.64M | -21.24M | -13.98M | -13.62M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -24.44M | -19.38M | -13.68M | -13.59M |
| ReconciledDepreciation | 39.00K | 30.00K | 25.00K | 24.00K |
| EBITDA | -26.64M | -21.24M | -13.98M | -13.62M |
| EBIT | -26.68M | -21.27M | -14.00M | -13.65M |
| NormalizedIncome | -24.44M | -19.38M | -13.68M | -13.59M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -24.44M | -19.38M | -13.68M | -13.59M |
| TotalExpenses | 26.68M | 21.27M | 14.00M | 13.65M |
| TotalOperatingIncomeAsReported | -26.68M | -21.27M | -14.00M | -13.65M |
| DilutedAverageShares | 40.40M | 32.57M | 26.44M | 20.77M |
| BasicAverageShares | 40.40M | 32.57M | 26.44M | 20.77M |
| DilutedEPS | -0.60 | -0.60 | -0.52 | -0.65 |
| BasicEPS | -0.60 | -0.60 | -0.52 | -0.65 |
| DilutedNIAvailtoComStockholders | -24.44M | -19.38M | -13.68M | -13.59M |
| NetIncomeCommonStockholders | -24.44M | -19.38M | -13.68M | -13.59M |
| NetIncome | -24.44M | -19.38M | -13.68M | -13.59M |
| NetIncomeIncludingNoncontrollingInterests | -24.44M | -19.38M | -13.68M | -13.59M |
| NetIncomeContinuousOperations | -24.44M | -19.38M | -13.68M | -13.59M |
| TaxProvision | 30.00K | 43.00K | 28.00K | 28.00K |
| PretaxIncome | -24.41M | -19.34M | -13.65M | -13.56M |
| OtherIncomeExpense | 2.27M | 1.93M | 353.00K | 82.00K |
| OtherNonOperatingIncomeExpenses | 2.27M | 1.93M | 353.00K | 82.00K |
| OperatingIncome | -26.68M | -21.27M | -14.00M | -13.65M |
| OperatingExpense | 26.68M | 21.27M | 14.00M | 13.65M |
| ResearchAndDevelopment | 19.06M | 13.11M | 7.84M | 8.77M |
| SellingGeneralAndAdministration | 7.62M | 8.16M | 6.16M | 4.88M |
| GeneralAndAdministrativeExpense | 7.62M | 8.16M | 6.16M | 4.88M |
| OtherGandA | 7.62M | 8.16M | 6.16M | 4.88M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 42.82M | 37.96M | 26.44M | 26.44M |
| ShareIssued | 42.82M | 37.96M | 26.44M | 26.44M |
| TotalDebt | 340.00K | 400.00K | 469.00K | 52.00K |
| TangibleBookValue | 40.72M | 51.06M | 31.83M | 44.02M |
| InvestedCapital | 40.72M | 51.06M | 31.83M | 44.02M |
| WorkingCapital | 39.22M | 50.89M | 31.67M | 43.91M |
| NetTangibleAssets | 40.72M | 51.06M | 31.83M | 44.02M |
| CapitalLeaseObligations | 340.00K | 400.00K | 469.00K | 52.00K |
| CommonStockEquity | 40.72M | 51.06M | 31.83M | 44.02M |
| TotalCapitalization | 40.72M | 51.06M | 31.83M | 44.02M |
| TotalEquityGrossMinorityInterest | 40.72M | 51.06M | 31.83M | 44.02M |
| StockholdersEquity | 40.72M | 51.06M | 31.83M | 44.02M |
| GainsLossesNotAffectingRetainedEarnings | 23.00K | 6.00K | -74.00K | -51.00K |
| OtherEquityAdjustments | 23.00K | 6.00K | -74.00K | -51.00K |
| RetainedEarnings | -140.00M | -115.56M | -96.18M | -82.50M |
| AdditionalPaidInCapital | 180.70M | 166.61M | 128.08M | 126.58M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 5.63M | 3.10M | 2.57M | 1.53M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 237.00K | 317.00K | 400.00K | 3.00K |
| LongTermDebtAndCapitalLeaseObligation | 237.00K | 317.00K | 400.00K | 3.00K |
| LongTermCapitalLeaseObligation | 237.00K | 317.00K | 400.00K | 3.00K |
| CurrentLiabilities | 5.39M | 2.79M | 2.17M | 1.52M |
| CurrentDebtAndCapitalLeaseObligation | 103.00K | 83.00K | 69.00K | 49.00K |
| CurrentCapitalLeaseObligation | 103.00K | 83.00K | 69.00K | 49.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.06M | 766.00K | 667.00K | 484.00K |
| PayablesAndAccruedExpenses | 4.23M | 1.94M | 1.43M | 991.00K |
| CurrentAccruedExpenses | 3.29M | 1.01M | 698.00K | 482.00K |
| Payables | 940.00K | 926.00K | 734.00K | 509.00K |
| AccountsPayable | 940.00K | 926.00K | 734.00K | 509.00K |
| TotalAssets | 46.34M | 54.16M | 34.40M | 45.55M |
| TotalNonCurrentAssets | 1.74M | 485.00K | 560.00K | 112.00K |
| NonCurrentPrepaidAssets | 1.31M | 0.00 | ||
| NetPPE | 427.00K | 485.00K | 560.00K | 112.00K |
| AccumulatedDepreciation | -114.00K | -100.00K | -80.00K | -67.00K |
| GrossPPE | 541.00K | 585.00K | 640.00K | 179.00K |
| Leases | 16.00K | 16.00K | 16.00K | 1.00K |
| OtherProperties | 42.00K | |||
| MachineryFurnitureEquipment | 246.00K | 215.00K | 200.00K | 136.00K |
| BuildingsAndImprovements | 279.00K | 354.00K | 424.00K | 42.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 44.61M | 53.67M | 33.84M | 45.44M |
| OtherCurrentAssets | 227.00K | 411.00K | 251.00K | 197.00K |
| PrepaidAssets | 411.00K | 251.00K | 197.00K | |
| Receivables | 236.00K | 369.00K | 82.00K | 130.00K |
| OtherReceivables | 2.00K | |||
| AccruedInterestReceivable | 235.00K | 298.00K | 80.00K | 130.00K |
| AccountsReceivable | 1.00K | 71.00K | 2.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 44.15M | 52.90M | 33.50M | 45.11M |
| OtherShortTermInvestments | 41.12M | 48.35M | 28.77M | 40.41M |
| CashAndCashEquivalents | 3.02M | 4.54M | 4.73M | 4.71M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -22.10M | -18.75M | -11.59M | -12.27M |
| RepaymentOfDebt | -9.00K | -6.00K | -6.00K | -6.00K |
| IssuanceOfCapitalStock | 11.75M | 36.85M | 0.00 | 29.85M |
| CapitalExpenditure | -25.00K | -24.00K | -81.00K | -22.00K |
| IncomeTaxPaidSupplementalData | 26.00K | 33.00K | 27.00K | 28.00K |
| EndCashPosition | 3.02M | 4.54M | 4.73M | 4.71M |
| BeginningCashPosition | 4.54M | 4.73M | 4.71M | 7.41M |
| ChangesInCash | -1.52M | -185.00K | 21.00K | -2.70M |
| FinancingCashFlow | 11.99M | 36.84M | -6.00K | 30.09M |
| CashFlowFromContinuingFinancingActivities | 11.99M | 36.84M | -6.00K | 30.09M |
| ProceedsFromStockOptionExercised | 256.00K | 0.00 | 0.00 | 244.00K |
| NetCommonStockIssuance | 11.75M | 36.85M | 0.00 | 29.85M |
| CommonStockIssuance | 11.75M | 36.85M | 0.00 | 29.85M |
| NetIssuancePaymentsOfDebt | -9.00K | -6.00K | -6.00K | -6.00K |
| NetLongTermDebtIssuance | -9.00K | -6.00K | -6.00K | -6.00K |
| LongTermDebtPayments | -9.00K | -6.00K | -6.00K | -6.00K |
| InvestingCashFlow | 8.56M | -18.30M | 11.54M | -20.54M |
| CashFlowFromContinuingInvestingActivities | 8.56M | -18.30M | 11.54M | -20.54M |
| NetInvestmentPurchaseAndSale | 8.59M | -18.27M | 11.62M | -20.52M |
| SaleOfInvestment | 59.00M | 51.13M | 57.30M | 49.30M |
| PurchaseOfInvestment | -50.41M | -69.41M | -45.68M | -69.81M |
| NetPPEPurchaseAndSale | -25.00K | -24.00K | -81.00K | -20.00K |
| SaleOfPPE | 0.00 | 2.00K | ||
| PurchaseOfPPE | -25.00K | -24.00K | -81.00K | -22.00K |
| OperatingCashFlow | -22.08M | -18.73M | -11.51M | -12.25M |
| CashFlowFromContinuingOperatingActivities | -22.08M | -18.73M | -11.51M | -12.25M |
| ChangeInWorkingCapital | 1.51M | 93.00K | 585.00K | -461.00K |
| ChangeInPayablesAndAccruedExpense | 2.50M | 540.00K | 591.00K | -548.00K |
| ChangeInAccruedExpense | 2.49M | 348.00K | 366.00K | 42.00K |
| ChangeInPayable | 14.00K | 192.00K | 225.00K | -590.00K |
| ChangeInAccountPayable | 14.00K | 192.00K | 225.00K | -590.00K |
| ChangeInPrepaidAssets | -1.12M | -160.00K | -54.00K | -123.00K |
| ChangeInReceivables | 133.00K | -287.00K | 48.00K | 210.00K |
| OtherNonCashItems | 75.00K | 70.00K | 64.00K | 58.00K |
| StockBasedCompensation | 2.08M | 1.68M | 1.50M | 1.56M |
| AmortizationOfSecurities | -1.34M | -1.22M | -11.00K | 161.00K |
| DepreciationAmortizationDepletion | 39.00K | 30.00K | 25.00K | 24.00K |
| DepreciationAndAmortization | 39.00K | 30.00K | 25.00K | 24.00K |
| Depreciation | 39.00K | 30.00K | 25.00K | 24.00K |
| NetIncomeFromContinuingOperations | -24.44M | -19.38M | -13.68M | -13.59M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for DMAC
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|